Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17257452 | MILK VESICLES FOR USE IN DELIVERING BIOLOGICAL AGENTS | December 2020 | July 2024 | Abandon | 42 | 3 | 0 | No | No |
| 16969040 | COMPOSITION FOR INCREASING EXPRESSION OF BLOOD COAGULATION FACTOR GENE, COMPRISING CORE-SHELL STRUCTURED MICROPARTICLES AS ACTIVE INGREDIENT | December 2020 | April 2023 | Abandon | 32 | 2 | 0 | No | No |
| 17119001 | SYSTEMS AND METHODS FOR TARGETED BREAST CANCER THERAPIES | December 2020 | August 2023 | Allow | 32 | 1 | 0 | No | No |
| 17251223 | PHARMACEUTICAL COMPOSITIONS IN LYOPHILIZED FORM | December 2020 | October 2023 | Abandon | 34 | 3 | 0 | No | No |
| 17118229 | INHALABLE PHARMACEUTICAL COMPOSITIONS | December 2020 | January 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17112547 | siRNA Nanocapsule and Preparation Method and Use thereof | December 2020 | June 2023 | Allow | 30 | 1 | 1 | No | No |
| 16972362 | METHODS FOR DIAGNOSING BRUGADA SYNDROME USING AN AEROSOL | December 2020 | May 2024 | Abandon | 42 | 1 | 0 | No | No |
| 16950327 | NANOPARTICLE DELIVERY SYSTEM FOR DISEASES ASSOCIATED WITH MAJOR BASEMENT MEMBRANE COMPONENTS OF BLOOD VESSELS ACCESSIBLE FROM BLOOD STREAM | November 2020 | April 2022 | Allow | 17 | 1 | 0 | No | No |
| 17097530 | METHOD OF LYOPHILIZING LIPOSOMES | November 2020 | October 2022 | Abandon | 23 | 1 | 0 | No | No |
| 17085836 | SUSTAINED RELEASE OF ANTIINFECTIVES | October 2020 | October 2022 | Abandon | 24 | 1 | 0 | No | No |
| 17052070 | METHODS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS | October 2020 | December 2024 | Abandon | 49 | 4 | 0 | No | Yes |
| 17079759 | LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION | October 2020 | May 2022 | Allow | 19 | 1 | 0 | No | No |
| 17050556 | MULTI-VESICULAR LIPOSOMES FOR TARGETED DELIVERY OF DRUGS AND BIOLOGICS FOR TISSUE ENGINEERING | October 2020 | February 2023 | Allow | 27 | 1 | 0 | No | No |
| 17075877 | METHOD FOR PREVENTING OR TREATING HIGH-GRADE SEROUS CARCINOMA | October 2020 | November 2023 | Abandon | 37 | 3 | 0 | No | No |
| 17048909 | TREATMENT OF SEPSIS AND SEPTIC SHOCK | October 2020 | April 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17073437 | COMPOSITION OF DOCETAXEL LIPOSOMAL INJECTION WITH HIGH DRUG LOADING | October 2020 | August 2023 | Allow | 34 | 2 | 0 | No | No |
| 17047666 | TREATMENT OF PNEUMONIA | October 2020 | March 2024 | Allow | 41 | 4 | 0 | No | Yes |
| 17066034 | COMPOSITION OF MATTER COMPRISING LIPOSOMES EMBEDDED IN A POLYMERIC MATRIX AND METHODS OF USING SAME | October 2020 | August 2023 | Allow | 34 | 3 | 0 | No | No |
| 17045940 | INHALABLE LIPOSOMAL SUSTAINED RELEASE COMPOSITION FOR USE IN TREATING PULMONARY DISEASES | October 2020 | August 2022 | Allow | 23 | 2 | 0 | No | No |
| 17044768 | PHYTATES FOR USE AS A BIOMOLECULES DELIVERY OR ADSORPTION SYSTEM | October 2020 | October 2022 | Allow | 24 | 3 | 0 | No | No |
| 17000829 | BIPHASIX CANNABINOID DELIVERY | August 2020 | January 2023 | Abandon | 29 | 2 | 0 | No | No |
| 16971095 | PLECTIN-TARGETED LIPOSOMES/PARP INHIBITOR IN THE TREATMENT OF CANCER | August 2020 | September 2023 | Allow | 37 | 3 | 0 | Yes | No |
| 16987282 | LIPOSOMAL FORMULATIONS AND METHODS OF USING SAME IN AGRICULTURE | August 2020 | July 2024 | Abandon | 48 | 7 | 0 | No | No |
| 16966310 | PARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS INTO ADIPOSE STROMAL CELLS | July 2020 | September 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16937545 | LIPOSOMAL NUTRACEUTICAL COMPOSITIONS AND METHODS OF MAKING THE SAME | July 2020 | October 2023 | Abandon | 39 | 2 | 1 | No | No |
| 16962956 | TREATING MICROVASCULAR DYSFUNCTION | July 2020 | October 2022 | Allow | 27 | 4 | 0 | Yes | No |
| 16928424 | LIPOSOMAL FORMULATION OF MOEXITECAN | July 2020 | January 2022 | Abandon | 18 | 2 | 0 | No | No |
| 16924539 | TAILORED LIPOSOMES FOR THE TREATMENT OF BACTERIAL INFECTIONS | July 2020 | January 2022 | Abandon | 19 | 1 | 0 | No | No |
| 16921964 | LIPOSOME COMPOSITION WITH ADIPOCYTE SPECIFICITY AND PREPARATION PROCESS THEREOF | July 2020 | August 2023 | Abandon | 38 | 3 | 0 | No | No |
| 16920979 | FUSOGENIC LIPOSOME-COATED POROUS SILICON NANOPARTICLES | July 2020 | April 2022 | Allow | 21 | 1 | 0 | No | No |
| 16919790 | PRE-FILLED SYRINGE CONTAINING SUGAMMADEX | July 2020 | April 2021 | Allow | 9 | 2 | 1 | Yes | Yes |
| 16919741 | ZINC MELOXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND PROCESSES FOR MAKING THE SAME | July 2020 | February 2021 | Allow | 8 | 0 | 0 | Yes | No |
| 16959617 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | July 2020 | June 2023 | Abandon | 36 | 3 | 0 | No | No |
| 16946572 | COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS | June 2020 | December 2022 | Abandon | 30 | 3 | 0 | No | No |
| 16955319 | MICROEMULSION FOR OPTHALMIC DRUG DELIVERY | June 2020 | May 2024 | Abandon | 47 | 3 | 1 | No | No |
| 16766127 | SUSTAINED-RELEASE TRIPTAN COMPOSITIONS AND METHOD OF USE THE SAME THROUGH SUBDERMAL ROUTE OR THE LIKE | May 2020 | April 2022 | Allow | 22 | 4 | 0 | No | Yes |
| 15930532 | PHARMACEUTICAL COMPOSITION OF A WEAK ACID DRUG AND METHODS OF ADMINISTRATION | May 2020 | April 2024 | Allow | 47 | 7 | 0 | Yes | No |
| 16868702 | Solution Preparation for Aerosol Inhalation of Carbocisteine, and Preparation Method Therefor | May 2020 | April 2022 | Abandon | 24 | 3 | 0 | Yes | No |
| 16856349 | Sterically Stabilized Carrier for Aerosol Therapeutics, Compositions and Methods for Treating the Respiratory Tract of a Mammal | April 2020 | January 2022 | Allow | 20 | 2 | 0 | Yes | Yes |
| 16856766 | METHODS OF INHIBITING ENVELOPED VIRUSES USING LOW MOLECULAR WEIGHT HYDROPHOBICALLY MODIFIED POLYMERS | April 2020 | March 2023 | Allow | 34 | 4 | 0 | Yes | Yes |
| 16854653 | MICROPARTICLE-BASED ENZYME SYSTEMS FOR SELECTIVE REMOVAL OF TARGET MOLECULES | April 2020 | March 2023 | Allow | 35 | 3 | 1 | No | No |
| 16837115 | PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA | April 2020 | December 2022 | Allow | 33 | 2 | 0 | Yes | No |
| 16825612 | HYDROGEL COMPOSITION FOR DRUG DELIVERY AND USES THEREOF | March 2020 | March 2023 | Allow | 36 | 3 | 0 | No | No |
| 16648524 | Process for Preparing a Powdered Composition | March 2020 | December 2021 | Allow | 21 | 3 | 0 | No | No |
| 16648026 | ARTIFICIAL BETA CELLS AND METHODS OF USE THEREOF | March 2020 | March 2022 | Allow | 24 | 3 | 0 | No | No |
| 16818078 | OCULAR DRUG DELIVERY SYSTEM AND USES THEREOF | March 2020 | January 2021 | Allow | 10 | 0 | 0 | No | No |
| 16646528 | COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS AND METHODS OF USE AND MAKING THEREOF | March 2020 | July 2024 | Abandon | 52 | 7 | 0 | Yes | No |
| 16811759 | NOVEL TETRAHYDROCURCUMIN COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USING THE SAME | March 2020 | June 2024 | Allow | 51 | 4 | 1 | No | Yes |
| 16809816 | PHOSPHATIDYLCHOLINE LIPID LIPOSOMES AS BOUNDARY LUBRICANTS IN AQUEOUS MEDIA | March 2020 | August 2022 | Allow | 29 | 3 | 0 | No | No |
| 16808004 | TUMOR THERAPEUTIC AGENT AND KIT CONTAINING GEMCITABINE LIPOSOME COMPOSITION | March 2020 | June 2021 | Allow | 16 | 2 | 0 | Yes | Yes |
| 16788083 | FREEZE-DRIED PRODUCT AND GAS-FILLED MICROVESICLES SUSPENSION | February 2020 | June 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16786194 | LIPOSOMES FOR DRUG DELIVERY AND METHODS FOR PREPARATION THEREOF | February 2020 | June 2021 | Allow | 16 | 2 | 0 | No | No |
| 16636560 | MULTI-FUNCTIONALIZED noMV CONJUGATES | February 2020 | September 2023 | Allow | 43 | 3 | 0 | Yes | No |
| 16780642 | TOPICAL CO-ENZYME Q10 FORMULATIONS AND TREATMENT OF PAIN, FATIGUE AND WOUNDS | February 2020 | June 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16634764 | ADRENALIN-CONTAINING DOUBLE LAYERED LIPID VESICLES FOR USE IN THE TREATMENT OF CARDIAC EMERGENCIES | January 2020 | April 2022 | Abandon | 26 | 3 | 0 | No | No |
| 16631566 | LIPOSOMAL PACLITAXEL FORMULATION FOR TREATING BLADDER CANCER | January 2020 | February 2022 | Abandon | 25 | 2 | 0 | No | No |
| 16629780 | Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses Thereof | January 2020 | October 2024 | Abandon | 57 | 4 | 0 | No | No |
| 16629686 | General and Direct Method for Preparing Oligonucleotide-Functionalized Metal-Organic Framework Nanoparticles | January 2020 | February 2023 | Allow | 37 | 1 | 1 | No | No |
| 16626434 | LIPONUCLEOTIDE-BASED THERAPY FOR COPD | December 2019 | June 2021 | Allow | 17 | 2 | 0 | Yes | No |
| 16626437 | LIPONUCLEOTIDE-BASED THERAPY FOR ASTHMA | December 2019 | August 2023 | Allow | 43 | 4 | 0 | Yes | Yes |
| 16626408 | NANOSOME FORMULATIONS OF APREPITANT AND METHODS AND APPLICATIONS THEREOF | December 2019 | January 2022 | Allow | 25 | 5 | 0 | Yes | No |
| 16623363 | A Method for Preparing a Functional Synthetic Cell in Form of a Giant Unilamellar Vesicle | December 2019 | April 2022 | Allow | 28 | 2 | 0 | No | No |
| 16713027 | FORMULATION COMPRISING LIPOSOMES | December 2019 | June 2020 | Allow | 6 | 1 | 0 | No | No |
| 16708120 | OPHTHALMIC FORMULATIONS PROVIDING DURABLE OCULAR LUBRICATION | December 2019 | January 2022 | Allow | 25 | 5 | 0 | Yes | No |
| 16705523 | Method for Enhancing Passenger Molecule Loading | December 2019 | July 2023 | Allow | 43 | 3 | 0 | No | Yes |
| 16700558 | Liposomal Mitigation of Drug-Induced Inhibition of the Cardiac IKR Channel | December 2019 | July 2023 | Abandon | 44 | 5 | 1 | No | No |
| 16618547 | GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG DELIVERY | December 2019 | April 2021 | Allow | 16 | 1 | 0 | No | No |
| 16616651 | LONG-CIRCULATING LIPOSOME MODIFIED WITH C(RGD-ACP-K) | November 2019 | October 2021 | Allow | 23 | 2 | 0 | No | No |
| 16687368 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | November 2019 | March 2022 | Allow | 28 | 3 | 1 | No | No |
| 16680283 | LIPOSOMAL CORTICOSTEROIDS FOR TREATMENT OF INFLAMMATORY DISORDERS IN HUMANS | November 2019 | July 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16612061 | NUCLEIC ACID VECTOR TABLETS | November 2019 | May 2024 | Allow | 54 | 5 | 0 | Yes | Yes |
| 16611508 | EMULSIFIED LIPOSOME COMPOSITION AND PREPARATION PROCESS THEREOF | November 2019 | July 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16611768 | COMPOSITIONS FOR FACILITATING MEMBRANE FUSION AND USES THEREOF | November 2019 | October 2022 | Allow | 35 | 1 | 0 | No | No |
| 16660263 | TREATMENT FOR GLIOBLASTOMA | October 2019 | October 2024 | Abandon | 60 | 8 | 1 | No | No |
| 16657347 | FUSOGENIC LIPOSOMES, COMPOSITIONS, KITS AND USE THEREOF FOR TREATING CANCER | October 2019 | April 2023 | Allow | 41 | 3 | 1 | No | No |
| 16601733 | DMS (derma membrane structure) in Foam Creams | October 2019 | June 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16603045 | LIPOSOMAL ANTI-INFECTIVE FORMULATIONS TO INHIBIT NON-TUBERCULOUS MYCOBACTERIA (NTM) MICROAGGREGATE FORMATION AND ESTABLISHMENT OF NTM BIOFILM | October 2019 | February 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16603111 | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS, E.G., SUBCUTANEOUSLY ADMINISTERED THERAPEUTIC PROTEINS | October 2019 | October 2023 | Allow | 49 | 4 | 0 | No | No |
| 16592263 | NANOPARTICLE ARSENIC-PLATINUM COMPOSITIONS | October 2019 | January 2022 | Abandon | 28 | 0 | 1 | No | No |
| 16585347 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | September 2019 | June 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16583518 | LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION | September 2019 | March 2022 | Allow | 29 | 4 | 0 | Yes | Yes |
| 16498137 | Compartmentalised Gel Matrix And Method Of Production | September 2019 | December 2021 | Allow | 26 | 1 | 0 | No | No |
| 16495164 | USE OF LIPOSOMES FOR TREATMENT OF CHRONIC VIRAL HEPATITIS B | September 2019 | May 2022 | Abandon | 32 | 3 | 1 | Yes | No |
| 16494551 | ENGINEERED LIPOSOMES AS CANCER-TARGETED THERAPEUTICS | September 2019 | October 2021 | Allow | 25 | 4 | 0 | Yes | No |
| 16489783 | IN SITU LIPID SYNTHESIS FOR PROTEIN RECONSTITUTION | August 2019 | January 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16554797 | LIPOSOMAL REHYDRATION SALT FORMULATION AND ASSOCIATED METHODS OF USE | August 2019 | April 2020 | Allow | 8 | 1 | 0 | No | No |
| 16488516 | LIPOSOMES FOR INHIBITING BIOFILM FORMATION | August 2019 | July 2021 | Abandon | 23 | 1 | 0 | No | No |
| 16485855 | LIPOSOMIC DRUG-DELIVERY VEHICLES | August 2019 | February 2023 | Allow | 60 | 4 | 1 | Yes | No |
| 16516493 | NANOCOCHLEATE FORMULATION AND METHOD OF PREPARING THE NANOCOCHLEATE FORMULATION | July 2019 | March 2021 | Abandon | 20 | 3 | 0 | No | No |
| 16478278 | HYPERSTABILIZED LIPOSOMES INCREASE TARGETING OF MITOTIC CELLS | July 2019 | February 2022 | Allow | 31 | 6 | 0 | Yes | No |
| 16476220 | COMPOSITION FOR PREVENTING OR TREATING METASTATIC OVARIAN CANCER, ENDOMETRIAL CANCER OR BREAST CANCER | July 2019 | July 2023 | Allow | 49 | 4 | 0 | Yes | Yes |
| 16476080 | Tetravalent Platinum Compound-Bicyclic Double-bond-containing Amphiphilic Polymer Prodrug, Nano-micelle, Preparation Method and Application Thereof | July 2019 | December 2020 | Allow | 18 | 0 | 1 | No | No |
| 16475524 | TREATMENT OF PANCREATIC CANCER | July 2019 | April 2022 | Abandon | 34 | 4 | 0 | Yes | No |
| 16454555 | REMOTE LOADING OF SPARINGLY WATER-SOLUBLE DRUGS INTO LIPOSOMES | June 2019 | March 2020 | Allow | 9 | 1 | 0 | No | No |
| 16448588 | INTRAOCULAR DELIVERY OF BIOACTIVE MOLECULES USING IONTOPHORESIS | June 2019 | October 2023 | Abandon | 52 | 6 | 0 | Yes | No |
| 16470411 | ORAL CARE COMPOSITION CONTAINING AT LEAST ONE BIOSURFACTANT AND FLUORIDE | June 2019 | June 2022 | Allow | 36 | 5 | 0 | Yes | No |
| 16470368 | Anti-Cancer Agents | June 2019 | August 2021 | Abandon | 26 | 2 | 0 | No | No |
| 16440189 | STABLE LIPOSOMES FOR DRUG DELIVERY | June 2019 | February 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16469162 | COMPOSITION FOR TRANSDERMAL DELIVERY OF MICRONUTRIENTS AND METHOD OF PREPARATION THEREOF | June 2019 | December 2021 | Abandon | 30 | 3 | 0 | No | No |
| 16432498 | LIPOSOMAL MITIGATION OF DRUG-INDUCED INHIBITION OF THE CARDIAC IKR CHANNEL | June 2019 | February 2024 | Allow | 56 | 8 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KISHORE, GOLLAMUDI S.
With a 31.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KISHORE, GOLLAMUDI S works in Art Unit 1612 and has examined 1,047 patent applications in our dataset. With an allowance rate of 32.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner KISHORE, GOLLAMUDI S's allowance rate of 32.6% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KISHORE, GOLLAMUDI S receive 2.85 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KISHORE, GOLLAMUDI S is 46 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +36.7% benefit to allowance rate for applications examined by KISHORE, GOLLAMUDI S. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.2% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 12.5% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 47.8% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 43% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 61.7% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 41.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 61.5% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.8% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.8% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.